Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final ...

Multiple sclerosis does not worsen menopause symptoms, study finds

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with ...
Neurology Advisor

FDA Extends Review Period for Novel MS Drug Tolebrutinib

The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...

Diabetes drug and antihistamine could together repair multiple sclerosis damage, trial finds

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...

MS trial results suggest drugs could repair damage

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may repair damage caused by the condition.

Hope for MS sufferers over drugs that 'can repair damaged nerves'

MS causes the body to attack myelin, the protective membrane around nerve cells, causing debilitating symptoms such as ...